Naushira Pandya
Geriatric Medicine · Davie, FLNPI 1275692584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,219 of the $144,742 with a category attached, or 74.1%. Lilly USA, LLC accounts for 77.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $43,708 and has fallen 98.4% since, to $691 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $670.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$112K
- AstraZeneca$17K
- Sanofi-aventis U.S. LLC$5K
- BD$4K
- Roche Diagnostics Corporation$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- plus $2K from 19 others
Across 3 payments — averaging $1040.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$3K
What the payments were for
- Consulting fees$22,42115%
- Speaking & faculty fees$107,21974%
- Grants$7501%
- Travel & lodging$10,2577%
- Food & beverage$4,0843%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 146 | $112,318 |
| AstraZeneca | 18 | $16,993 |
| Sanofi-aventis U.S. LLC | 10 | $5,245 |
| BD | 1 | $4,100 |
| Roche Diagnostics Corporation | 1 | $2,900 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,063 |
| Abbott | 3 | $341 |
| Novo Nordisk | 4 | $263 |
| Amgen | 6 | $198 |
| Corcept Therapeutics | 4 | $174 |
| Pharming Healthcare, Inc. | 2 | $144 |
| Mylan Specialty L.p. | 4 | $141 |
| Acadia Pharmaceuticals Inc | 1 | $120 |
| Viatris Specialty LLC | 2 | $111 |
| CSL Behring | 1 | $102 |
| Pfizer | 1 | $89 |
| Otsuka America Pharmaceutical, Inc. | 1 | $87 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $83 |
| Sunovion Pharmaceuticals Inc. | 1 | $61 |
| Johnson & Johnson | 1 | $50 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $47 |
| Medtronic | 1 | $38 |
| Insulet Corporation | 1 | $27 |
| Urovant Sciences Inc | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$144,742 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 12 | $18,343 |
| OzempicSemaglutide | 13 | $16,521 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,939 |
| FarxigaDapagliflozin Propanediol | 11 | $9,752 |
| Levothyroxine Sodium | 22 | $302 |
| Metformin Hcl | 31 | $268 |
| Atorvastatin Calcium | 35 | $255 |
| Verapamil Hcl | 11 | $164 |
| Losartan Potassium | 11 | $125 |
| Trazodone Hcl | 12 | $114 |
| Glipizide | 11 | $60 |
| Amlodipine Besylate | 18 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $263 | $34,86425 claims |
| AstraZenecaFarxiga | $16,993 | $9,75211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Davie
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
- Jason StibichBrandon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.